1 results match your criteria: "and Jinan Central Hospital and Clinical Medical College of Shandong University[Affiliation]"
Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin.
J Biochem
August 2008
Institute of Biochemical and Biotechnological Drug, School of Pharmaceutical Science, National Glycoengineering Research Center, Shandong University, and Jinan Central Hospital and Clinical Medical College of Shandong University, Jinan, China.
Endostatin (ES), as an angiogenesis inhibitor, has been approved by the State Food and Drug Administration (SFDA) in China for the treatment of patients with non-small-cell lung cancer. However, as a protein drug, there are a lot of obstacles on its clinical application, such as need of high dose to maintain its efficacy, expensive and poor stability, etc and limits its clinical use. In order to overcome these shortcomings, we chemically modified ES by polyethylene glycol and low molecular weight heparin (LMWH), respectively.
View Article and Find Full Text PDF